Biocon Biologics has achieved a major milestone by closing its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what Biocon management described as a “historic inflection point” for the Indian biosimilars player.
Biocon Closes $3bn Deal For Viatris Biosimilars
Cites ‘Historic Inflection Point’ For Biocon Biologics As Viatris Also Begins Transformation
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.
More from Deals
More from Business
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.